Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.33 USD | -0.27% | +0.09% | -19.36% |
May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
May. 01 | Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.36% | 81.46B | |
+29.68% | 681B | |
+19.58% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+14.02% | 235B | |
+4.34% | 199B | |
-12.02% | 189B | |
-3.79% | 157B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- IDEAYA Biosciences Collaborates With Gilead Sciences to Evaluate Combination of Trodelvy, IDE397 for Bladder Cancer